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Abstract
Introduction—Hepatitis C virus (HCV) infection is an important contributor to the worldwide 
burden of liver-related morbidity and mortality. Mother-to-child transmission of HCV ranges from 
6 to 11% in different populations globally, but accurate estimates on the burden of pediatric HCV 
infection are limited because screening approaches are not consistent.
Areas covered—The advent of new direct-acting antiviral agents that achieve very high rates of 
sustained virologic response (representing virologic cure) with short (i.e. 8–12 weeks) regimens 
has revolutionized the field of HCV treatment and led to the development of global elimination 
goals for HCV transmission and mortality. However, information on their safety during pregnancy 
and efficacy in preventing mother-to-child transmission is lacking. Currently, there are no 
approved treatment regimens with these antiviral agents for children younger than 12 years of age.
Expert commentary—If these agents are shown to be safe during pregnancy and effective in 
preventing transmission to the infant, screening of pregnant women and antenatal treatment of 
those infected, could pave the way for eliminating pediatric HCV infection-particularly as these 
drugs become less costly and more accessible. Treatment of infected children when indicated, 
along with universal safe health care practices, can further pediatric HCV elimination.
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1. Introduction
Hepatitis C virus (HCV), a small single-stranded RNA flavivirus, is a major contributor to 
the global burden of liver-related morbidity and mortality, and is responsible for an 
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estimated 27% of cirrhosis and 25% of hepatocellular cancer cases [1,2]. Worldwide, an 
estimated 71 million people are living with HCV infection, and only 20% of individuals are 
aware of their diagnosis [1,3–6]. The global prevalence of HCV infection varies by region 
[3]. In terms of absolute numbers, China, Pakistan, India, Egypt and Russia are the five 
countries with the highest numbers of individuals infected, at over 5 million people each [3]. 
The global incidence of HCV is estimated at 23.7 per 100,000 persons, with the highest 
incidence rates found in the African (31.0), and European and Eastern Mediterranean (61.8–
62.5) regions [1]. HCV has seven major genotypes (GT) and distinct subtypes, which vary in 
their geographic distribution and response to therapy [7,8], which has become less of an 
issue with the advent of new HCV antiviral therapies [1]. Worldwide, GT 1 is the most 
common (46%), followed by GT 3 (22%), GT 2 (13%) and GT 4 (13%) [7]. Genotypes 1–3 
are found globally while genotypes 4, 5, and 6 are most commonly found in northern Africa, 
South Africa and Asia, respectively [7]. The same distribution has been observed in both 
children and adults [9].
About 3.5 million people are estimated to be living with HCV infection in the United States 
(US) [10]. Individuals at risk for HCV infection include those with a history of injection 
drug use or history of blood or blood product transfusion prior to 1992, hemodialysis 
patients, children born to HCV-infected mothers and people living with HIV infection [8]. 
HIV positive individuals have a higher HCV prevalence; injection drug use accounts for the 
majority of such infections [1].
The most common mode of HCV transmission is through direct exposure to blood such as 
with injection drug use, parenteral exposure via contaminated medical equipment or 
transfusion of unscreened blood and blood products [1]. The HCV risk due to using 
contaminated medical equipment and transfusions in developed countries is inconsequential 
due to improved medical practices and routine screening of blood and its products whereas 
in developing countries infections due to transfusion and poor medical practice still occur 
[1,11]. Other known transmission routes include percutaneous exposure in health care 
personnel, and sexual transmission [1,12]. The risk of developing HCV infection after 
percutaneous exposure in occupational settings is low and estimated at 1.9% or less [13]. 
Sexual transmission of HCV infection is uncommon, although it has occurred in HIV-
positive men who have sex with men [14,15]. There is no evidence of transmission through 
saliva or non-sexual casual transmission [16,17]. Due to the nature of transmission, there is 
no requirement to exclude children from daycare or schools [18]. Transmission typically 
does not occur in families but can occur in the presence of direct or inapparent percutaneous 
or mucosal exposure to blood [18]. In children, 60% of global incident cases of HCV 
infection are due to mother-to-child transmission, the predominant source of infection in this 
age category [9,19]. In areas with poor blood screening practices, transfusion-related 
pediatric infections still pose a challenge [20,21].
In 2016, the World Health Assembly (WHA) approved the Global Health Sector Strategy on 
Viral Hepatitis, 2016–2021 [22]. For hepatitis C, the 2030 goals of the strategy include 
targeting a 90% reduction in new cases, a 65% reduction in deaths and treatment of 80% 
eligible people [1,22]. Five core interventions are outlined: vaccination, prevention of 
mother-to-child transmission, safe healthcare practices, harm reduction services for people 
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who inject drugs and testing and treatment [22]. Only the last three interventions pertain to 
hepatitis C as there are no hepatitis C vaccines or current proven safe and effective 
approaches for the prevention of mother-to-child HCV transmission. In addition, there is 
also a dearth of approved treatment interventions for children under 12 years old. As 
progress is made toward the elimination goals, preventing mother-to-child transmission as 
well as treating and reducing HCV-related morbidities in children need to remain a key 
focus.
2. The new landscape of anti-HCV treatment
The latest class of antivirals for the treatment of HCV infection include second- and third-
generation direct-acting antivirals (DAAs) [5,23,24]. These DAAs are highly effective and 
most have not demonstrated fetal harm in animal studies [5,23]. These new agents are 
categorized in four main groups: protease inhibitors, such as simeprevir, glecaprevir; 
nucleotide analog polymerase inhibitors, such as sofosbuvir; nonnucleotide analogs, such as 
dasabuvir and nonstructural (NS5A) protein inhibitors, such as daclatasvir, velpatasvir, 
pibrentasvir or ledipasvir [24]. These DAAs, when used in combination regimens, result in 
high rates of sustained virologic response (SVR) representing virologic cure, usually 90% or 
higher when given in relatively short regimens [5]. These antivirals have revolutionized 
HCV treatment and are expected to have a major influence on the global epidemiology of 
HCV infection in the next few years. Some of these newer agents have activity against all 
HCV genotypes (pangenotypic), which is a significant advantage over the older genotype-
specific HCV therapies [1,25].
Despite the favorable profile of the newer DAAs, these agents lack sufficient human 
pregnancy safety data and are not approved for use during pregnancy. Preclinical and animal 
data on the safety of Sofosbuvir (SOF) and ledipasvir/sofosbuvir (LDF/SOF) suggest that 
they may be potential candidates for use during pregnancy. The University of Pittsburgh is 
currently conducting a phase I clinical trial on the use of LDF/SOF in pregnant women with 
chronic HCV infection [26]. The results of this trial may lead to options for treatment during 
pregnancy both for maternal treatment and potentially for prevention of transmission to the 
infant. Other pangenotypic regimens like sofosbuvir/velpatasvir (Epclusa) [27], the first 
FDA approved regimen to treat 6 HCV genotypes, need to also be tested in clinical trials 
during pregnancy, to ensure that treatment options are available regardless of HCV 
genotype.
3. HCV infection in pregnant women
There is a paucity of data on the prevalence of HCV infection among pregnant women since 
HCV testing during pregnancy is inconsistent. Although it appears to be similar to that of the 
general population of childbearing age, it is estimated at approximately 1% [28]. Higher 
prevalence rates have been reported in some populations; for instance, Egypt has reported a 
6% prevalence rate in pregnant women [29]. In the US, HCV incidence is on the rise in 
women of childbearing age concomitant with the opioid epidemic and increase in injection 
drug use [30,31].
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The impact of acute maternal HCV infection on mother-to-child transmission is not well 
defined; [23,32] acute infection is considered uncommon during pregnancy and challenging 
to diagnose without knowledge of the exposure [33]. Pregnancy does not appear to influence 
the course of HCV infection for the mother [32], although the HCV viral load peaks in the 
third trimester of gestation [34] while the levels of serum alanine aminotransferase (ALT) 
decrease during the second and third trimesters [35]. There is conflicting evidence on the 
relationship between HCV infection and adverse pregnancy outcomes such as preterm 
delivery [36,37], gestational diabetes, low birth weight, small for gestational age and 
cholestasis of pregnancy [33].
Approximately 6%–11% of children born to HCV-infected mothers acquire HCV [38]. It is 
likely that HCV is transmitted both in utero and at the time of delivery [39,40]. Based on the 
timing of detection of HCV RNA by PCR in the infants, the majority of infants are infected 
perinatally (either late in utero or intrapartum) similar to HIV-1 infection [41,42]. Factors 
that increase perinatal transmission of HCV include fetal monitoring, vaginal lacerations, 
and prolonged rupture of the membranes (>6 h) [18,33,35,43]. The method of delivery has 
no effect on transmission risk; thus, caesarean delivery is not recommended as a risk 
reduction strategy [44]. Breastfeeding is not thought to increase risk of transmission of HCV 
to the infant as long as the mother’s nipples are not cracked or bleeding [35]. When nipples 
are cracked or bleeding, mothers need to stop breastfeeding, and pump and discard their 
milk; breastfeeding can be resumed when the nipples have healed [18]. The risk of mother-
to-child transmission of HCV is greater in women with HIV coinfection. In the presence of 
HIV, the transmission rate doubles from 5.8% to 10.8% [38], likely due to an increase in 
HCV viremia [45,46]. For HIV and HCV co-infected women, HIV suppression with the use 
of highly active antiretroviral therapy (HAART) may reduce HCV transmission to infants 
[47].
HCV screening during pregnancy is generally risk-based. The main challenge of risk-based 
screening is the use of self-report to identify women with risk factors for infection [33] 
resulting in the possible underestimation of the HCV disease burden among pregnant women 
and of infant HCV infections acquired perinatally. Broader screening practices could 
identify cases of previously undiagnosed HCV infection [5,48], as for instance occurred in 
Italy, where HCV screening is now offered to all pregnant women in the third trimester of 
pregnancy [49]. Current recommendations by the Centers for Disease Control and 
Prevention (CDC) and organizations such as the World Health Organization, the American 
Congress of Obstetricians and Gynecologists (ACOG) and the US Preventive Services Task 
Force (USPSTF) call for risk-based HCV screening [8,50,51]. However, this practice is 
shifting. In 2018, the state of Kentucky passed legislation requiring universal HCV testing 
during pregnancy [52], and the American Association for the Study of Liver Diseases 
(AASLD) has now recommended universal screening during pregnancy [53]. Until now, 
universal screening has not been recommended in the U.S. due to the generally believed low 
prevalence of HCV infection and lack of approved prenatal approaches to prevent mother-to-
child transmission [23].
Cost-effectiveness analyses have validated both risk-based [54] and routine HCV screening 
in pregnant women [55]. With the new screening recommendations and the increased access 
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to newer antiviral agents, economic analyses on HCV screening should be updated with 
regard to testing strategies during pregnancy. Furthermore, as more women are screened and 
potentially diagnosed with HCV infection during pregnancy, the use of DAAs during 
pregnancy will become an important consideration.
Availability of modalities to prevent transmission of HCV from mother to infant could 
strengthen the rationale for universal HCV screening during pregnancy. Given that mothers 
with undetectable HCV viral load rarely transmit to their infants [23], suppressing viremia 
during pregnancy would be expected to prevent HCV transmission. But, as mentioned, the 
newer DAA agents lack sufficient safety data for use during pregnancy [5] and pregnancy is 
currently a contraindication to treatment. Information on the safety of DAAs during 
pregnancy would have obvious benefits for the pregnant women, as women may become 
pregnant while on treatment. For some women, pregnancy may represent the main 
opportunity for clinical care. Such information can be gathered from carefully designed 
clinical trials as well as from medication registries. Clinical trials are also needed to assess 
the efficacy of treatment during pregnancy in preventing transmission of HCV to the infant.
4. HCV infection in children
The current global estimate of the number of children under 15 years of age living with 
chronic HCV infection is 2.1 million [6]. Mother-to-child transmission is the leading cause 
of pediatric HCV infection and data from Pakistan and Egypt estimate that 25% and up to 
50% of HCV cases in children under 5 years of age, respectively, were due to perinatal 
transmission [56,57]. Pediatric HCV infection is typically asymptomatic and progresses 
slowly [58,59]. Time between HCV infection and disease development in children is highly 
variable and severe disease most likely occurs about 2 to 3 decades after infection [9,60]. An 
estimated 20% of infected children will experience natural clearance of the virus, usually 
during early infection, by approximately 2.5 years of age; the remainder will develop 
chronic infection [34,58,61]. As infected children age, the increased severity and 
progression of liver disease is expected [58]. Children with comorbidities also experience 
greater liver disease severity [58]. HIV co-infected children experience poorer health 
outcomes and are less likely to experience spontaneous clearance [61]. This is particularly 
important for sub-Saharan African countries with higher HIV-HCV coinfection rates [62]. 
Although the natural history of HCV in children is generally mild, development of liver 
disease can occur during childhood [59,63]. Extrahepatic manifestations of chronic hepatitis 
C frequently occurring in adults such as rashes, cryoglobulinemia, glomerulonephritis are 
less common in children [9]. However, when children present with these conditions, they are 
prioritized for treatment [53]. Children with HCV also experience reduced health-related 
quality of life when compared to children without HCV infection. Nydegger et al. 
demonstrated that children with asymptomatic HCV experienced lowered health scores in 
most health domains [64]. Rodrigue et al. found that some children may experience 
cognitive delays and caregivers had high levels of anxiety due to current and future 
considerations of the infected child’s wellbeing [65]. HCV treatment may be useful in 
raising quality of life scores and reducing the stress on caregivers; a study examining quality 
of life in adolescents after HCV treatment found that quality of life scores improved after 
treatment [66].
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Significant costs are associated with the provision of medical care for HCV-infected children 
in the US, estimated at $17 to $40 million per year [67]. The elimination of pediatric HCV 
infection is an important goal as pediatric infection is associated with advanced HCV-related 
conditions in adulthood that lead to morbidity and mortality and furthermore, it poses a huge 
economic burden. The treatment of pediatric HCV infection should be weighed against the 
probability of spontaneous clearance considering that children who experience spontaneous 
HCV clearance will usually do so by the age of two [9].
Pegylated interferon and ribavirin is the only approved HCV treatment regimen for children 
3 years and older but its use in routine practice is extremely limited due to adverse effects 
[68]. For children under the age of 3 years, there are no approved HCV treatment regimens. 
Recently, in 2017, LDF/SOF was approved as the first direct-acting antiviral for use in 
children between the ages of 12 and 17 years [69]. This advancement in treatment for 
pediatric HCV was based on a clinical trial that demonstrated the safety and efficacy of this 
drug in adolescents with HCV GT 1 infection [70]. Another clinical trial examined treatment 
efficacy of these drugs in young children (6–11 years old) with primarily HCV GT1 
infection, and found cure rates as high as 99% [71,72]. For children with HCV GT4 
infection, additional published results on the use of LDF/SOF have also shown high rates of 
SVR at 12 weeks in a small number of young children (6–12 years old) [73] and in 
adolescents (12–17 years old) [74]. Yakoot et al. examined the safety and efficacy of 
sofosbuvir/daclatasvir (SOF/DCV) in 30 adolescent patients and found high rates of SVR at 
12 weeks [75]. Several other pediatric HCV clinical trials investigating the safety and 
efficacy of the DAAs in children as young as 3 are currently ongoing [76]. The 2018 
AASLD HCV guidance now has recommendations for using DAAs for the treatment of 
adolescents and the treatment of all children older than 3 years old, if the DAAs are 
available for the particular age group [53].
A new era for the treatment of pediatric HCV infection is on the horizon, as there are 
enormous health and economic rewards to reap by early treatment in this population. 
Childhood HCV disease affects children, their families and caregivers; and adverse financial 
and psychological effects can occur [65,77]. The availability of safe and effective treatment 
options can alleviate this burden. To better understand the need for and benefits of treating 
pediatric HCV infection, results from the clinical trials will be paramount. Additional 
research on the economic benefits of childhood treatment, any differences in drug efficacy/
response, for instance, tolerability, in adults versus pediatric populations, long-term 
monitoring for disease recurrence or for drug toxicities, and factors that are associated with 
early clearance of the virus or disease progression are also necessary.
5. Conclusion
The WHO Global Health Sector Strategy goals, inspired by the availability of new therapies, 
have revolutionized the approaches to prevent and ultimately eliminate HCV transmission 
and disease. Treatment of all infected individuals has been proposed as the means to achieve 
the goals of HCV elimination. Yet, identifying everyone infected with HCV, as well as the 
cost and availability of the newer therapies, remain major barriers. Estimated costs for a 12 
week course of treatment currently range from approximately $150 to $500 in countries with 
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voluntary licensing agreements for the use of generic DAAs, to $50,000 in some high-
income countries [78]. In the US, this has resulted in the prioritization of patients with 
advanced liver disease and no substance abuse for treatment with DAAs [79]; however, as of 
now, newer treat-all recommendations are being introduced [53]. DAAs have a special role 
to play in meeting WHO viral hepatitis goals by 2030 [22]. WHO recommends the 
prioritization of HCV treatment, including optimizing drug financing mechanisms [1].
6. Expert commentary
Despite the advances in new drug development, critical knowledge gaps remain. Treating 
HCV infection during pregnancy and preventing HCV infection in children are two such 
gaps. More clinical trials focusing on the safety and efficacy of DAAs during pregnancy, 
infancy and early childhood are needed. Pregnancy registries could also provide important 
information as treatment is rolled out similar to the evidence gained by antiretroviral 
pregnancy registries. Through the use of antiretrovirals, prevention of mother-to-child 
transmission of HIV has been achieved and eliminating perinatal HIV transmission is now 
an attainable goal in the near future. This feat serves as a model for other disease areas and 
the use of newer antiviral agents is now proposed for prevention of breakthrough mother-to-
child transmission of hepatitis B virus [80]. Lessons learned from preventing mother-to-
child transmission of these two other viruses could benefit the field of HCV.
Treating HCV infection before and during pregnancy may lead to the prevention of vertical 
transmission and long-term infection in the infant. In addition to the health and 
psychological benefits for the mother and family, the economic burden of disease would also 
be alleviated. Demonstrating safety of DAAs during pregnancy as well as efficacy in 
preventing mother-to-child transmission of HCV could also lend further support to the 
argument for HCV screening for pregnant women.
7. Five-year view
Based on the current landscape of treatment of HCV with DAAs, in 5 years, we expect that 
more results from ongoing and planned clinical trials will be available and will help shape 
the discourse on HCV treatment policies of pregnant women and children. For children 
under 12 years old, we expect that DAA treatment options will be available. Economic 
analyses to support treatment of young children with DAAs will aid in treatment guidelines 
and policies. Considering the health and economic gains, children should have access to 
treatment, when indicated, regardless of cost. Policy changes for expanded screening during 
pregnancy (e.g. universal screening or expanded risk-based screening) may be implemented. 
Removing additional barriers to DAA access, such as cost [81], is also expected based on the 
current landscape.
Acknowledgments
Funding
The manuscript was not funded.
Declaration of interest
Nwaohiri et al. Page 7
Expert Rev Anti Infect Ther. Author manuscript; available in PMC 2019 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial 
interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes 
employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or 
pending, or royalties.
References
Papers of special note have been highlighted as either of interest (•) or of considerable 
interest (••) to readers.
1. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017 (Licence: CC BY-NC-SA 
3.0 IGO).
2. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C 
virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538. 
[PubMed: 16879891] 
3. The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of 
hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):
161–176. [PubMed: 28404132] 
4. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic 
hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 
2012;61(RR-4):1–32.
5. Spera AM, Eldin TK, Tosone G, et al. Antiviral therapy for hepatitis C: has anything changed for 
pregnant/lactating women? World J Hepatol. 2016;8(12):557–565. [PubMed: 27134703] 
6. The Polaris Observatory HCV Collaborators. Data request. [cited 2018 Feb 8]. Available from: 
http://cdafound.org/polaris/
7. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C 
virus infection. J Hepatol. 2014;61(1 Suppl):S45–57. [PubMed: 25086286] 
8. World Health Organization: Guidelines for the Screening, Care and Treatment of Persons with 
Chronic Hepatitis C Infection, Updated Version, April 2016.
9. Squires JE, Balistreri WF. Hepatitis C virus infection in children and adolescents. Hepatol Commun. 
2017;1(2):87–98. [PubMed: 29404447] 
10. Edlin BR, Eckhardt BJ, Shu MA, et al. Toward a more accurate estimate of the prevalence of 
hepatitis C in the United States. Hepatology (Baltimore, Md). 2015;62(5):1353–1363.
11. Prati D Transmission of hepatitis C virus by blood transfusions and other medical procedures: a 
global review. J Hepatol. 2006;45 (4):607–616. [PubMed: 16901579] 
12. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436–
2441. [PubMed: 17552026] 
13. Hughes HY, Henderson DK. Postexposure prophylaxis after hepatitis C occupational exposure in 
the interferon-free era. Curr Opin Infect Dis. 2016;29(4):373–380. [PubMed: 27306563] 
14. Jin F, Matthews GV, Grulich AE. Sexual transmission of hepatitis C virus among gay and bisexual 
men: A systematic review. Sexual Health. 2017;14(1):28–41. [PubMed: 27712618] 
15. Chan DP, Sun HY, Wong HT, et al. Sexually acquired hepatitis C virus infection: a review. Int J 
Infect Dis. 2016;49:47–58. [PubMed: 27270138] 
16. Ackerman Z, Ackerman E, Paltiel O. Intrafamilial transmission of hepatitis C virus: a systematic 
review. J Viral Hepat. 2000;7 (2):93–103. [PubMed: 10760039] 
17. Ferreiro MC, Dios PD, Scully C. Transmission of hepatitis C virus by saliva? Oral Dis. 2005;11(4):
230–235. [PubMed: 15984954] 
18. Kimberlin DW, Long SS, Brady MT, et al. Red book 2018–2021: report of the committee on 
infectious diseases, 31st Hepatitis C. Itasca, IL: American Academy of Pediatrics;2018.
19. Lanini S, Easterbrook PJ, Zumla A, et al. Hepatitis C: global epidemiology and strategies for 
control. Clin Microbiol Infect. 2016;22 (10):833–838. [PubMed: 27521803] 
20. Atwa ZT, Abdel Wahed WY. Transfusion transmitted infections in frequently transfused 
thalassemic children living in fayoum governorate, Egypt: current prevalence and risk factors. J 
Infect Public Health. 2017;10(6):870–874. [PubMed: 28292647] 
Nwaohiri et al. Page 8
Expert Rev Anti Infect Ther. Author manuscript; available in PMC 2019 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
21. Kamal SM, Ghoraba D. Epidemiology and Modes of Transmission of HCV in Developing 
Countries In Kamal SM (Ed.). Hepatitis C in Developing Countries, Current and Future 
Challenges. Cambridge, MA: Academic Press 2018:13–24.
22. World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Geneva: 
World Health Organization; 2016.
23. Kanninen TT, Dieterich D, Asciutti S. HCV vertical transmission in pregnancy: new horizons in 
the era of DAAs. Hepatology (Baltimore, Md). 2015;62(6):1656–1658.
24. Hepatitis C Treatment.[cited 2017 June 9 ]. Available from: http://www.hepatitisc.uw.edu/page/
treatment/drugs
25. Weisberg IS, Jacobson IM. A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the 
treatment of chronic hepatitis C infection. Expert Opin Pharmacother. 2017;18(5):535–543. 
[PubMed: 28092171] 
26. Study of Hepatitis C Treatment During Pregnancy (HIP). [cited 2017 June 9]. Available from: 
https://clinicaltrials.gov/ct2/show/NCT02683005?term=HCV+pregnancy&rank=3
27. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 
6 infection. N Engl J Med. 2015;373 (27):2599–2607. [PubMed: 26571066] •• This trial 
demonstrated that Epclusa was an effective pangenotypic treatment for HCV.
28. Valladares G, Chacaltana A, Sjogren MH. The management of HCV-infected pregnant women. 
Ann Hepatol. 2010;9(Suppl):92–97. [PubMed: 20714003] 
29. Khamis HH, Farghaly AG, Shatat HZ, et al. Prevalence of hepatitis C virus infection among 
pregnant women in a rural district in Egypt. Trop Doct. 2016;46(1):21–27. [PubMed: 25515736] 
30. Patrick SW, Bauer AM, Warren MD, et al. Hepatitis C virus infection among women giving birth - 
tennessee and United States, 2009–2014. MMWR Morbidity and Mortality Weekly Report. 
2017;66(18):470–473. [PubMed: 28493860] 
31. Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug 
use among persons aged</=30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006–
2012. MMWR Morbidity and Mortality Weekly Report. 2015;64(17):453–458. [PubMed: 
25950251] 
32. Floreani A Hepatitis C and pregnancy. World journal of gastroenterology. 2013;19(40):6714–6720. 
[PubMed: 24187446] 
33. Prasad MR, Honegger JR. Hepatitis C virus in pregnancy. Am J Perinatol. 2013;30(2):149–159. 
[PubMed: 23389935] 
34. Le Campion A, Larouche A, Fauteux-Daniel S, et al. Pathogenesis of hepatitis C during pregnancy 
and childhood. Viruses. 2012;4 (12):3531–3550. [PubMed: 23223189] 
35. Yeung CY, Lee HC, Chan WT, et al. Vertical transmission of hepatitis C virus: current knowledge 
and perspectives. World J Hepatol. 2014;6 (9):643–651. [PubMed: 25276280] 
36. Huang QT, Huang Q, Zhong M, et al. Chronic hepatitis C virus infection is associated with 
increased risk of preterm birth: a meta-analysis of observational studies. J Viral Hepat. 
2015;22(12):1033–1042. [PubMed: 26081198] 
37. Jhaveri R, Swamy GK. Hepatitis C virus in pregnancy and early childhood: current understanding 
and knowledge deficits. J Pediatr Infect Dis Societ. 2014;3(Suppl 1):S13–8.
38. Benova L, Mohamoud YA, Calvert C, et al. Vertical transmission of hepatitis C virus: systematic 
review and meta-analysis. Clin Infect Dis. 2014;59(6):765–773. [PubMed: 24928290] • Benova et 
al. showed that HCV/HIV co-infected mothers had greater rates of vertical transmission of HCV to 
their infants.
39. Gibb DM, Goodall RL, Dunn DT, et al. Mother-to-child transmission of hepatitis C virus: evidence 
for preventable peripartum transmission. Lancet (London, England). 2000;356(9233):904–907.
40. Mok J, Pembrey L, Tovo PA, et al. European Paediatric Hepatitis CVN. When does mother to child 
transmission of hepatitis C virus occur? Arch Dis Child Educ Pract Ed. 2005;90(2):F156–60.
41. Polywka S, Pembrey L, Tovo PA, et al. Accuracy of HCV-RNA PCR tests for diagnosis or 
exclusion of vertically acquired HCV infection. J Med Virol. 2006;78(2):305–310. [PubMed: 
16372293] 
42. Kourtis AP, Bulterys M, Nesheim SR, et al. Understanding the timing of HIV transmission from 
mother to infant. Jama. 2001;285 (6):709–712. [PubMed: 11176886] 
Nwaohiri et al. Page 9
Expert Rev Anti Infect Ther. Author manuscript; available in PMC 2019 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
43. Dunkelberg JC, Berkley EM, Thiel KW, et al. Hepatitis B and C in pregnancy: a review and 
recommendations for care. J Perinatology. 2014;34(12):882–891.
44. Cottrell EB, Chou R, Wasson N, et al. Reducing risk for mother-to-infant transmission of hepatitis 
C virus: a systematic review for the U.S. preventive services task force. Ann Intern Med. 2013;158 
(2):109–113. [PubMed: 23437438] 
45. Polis CB, Shah SN, Johnson KE, et al. Impact of maternal HIV coinfection on the vertical 
transmission of hepatitis C virus: a meta-analysis. Clin Infect Dis. 2007;44(8):1123–1131. 
[PubMed: 17366462] 
46. Baroncelli S, Pirillo MF, Amici R, et al. HCV-HIV coinfected pregnant women: data from a 
multicentre study in Italy. Infection. 2016;44 (2):235–242. [PubMed: 26507133] 
47. Checa Cabot CA, Stoszek SK, Quarleri J, et al. Mother-to-child transmission of Hepatitis C Virus 
(HCV) among HIV/HCV-coinfected women. J Pediatr Infect Dis Societ. 2013;2(2):126–135.
48. Elrazek A, Amer M, El-Hawary B, et al. Prediction of HCV vertical transmission: what factors 
should be optimized using data mining computational analysis. Liver Int. 2017;37(4):529–533. 
[PubMed: 27125252] 
49. Tosone G, Maraolo AE, Mascolo S, et al. Vertical hepatitis C virus transmission: main questions 
and answers. World J Hepatol. 2014;6 (8):538–548. [PubMed: 25232447] 
50. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 86: viral 
hepatitis in pregnancy. Obstet Gynecol. 2007;110(4):941. [PubMed: 17906043] 
51. Moyer VA. Screening for hepatitis C virus infection in adults: US preventive services task force 
recommendation statement. Ann Intern Med. 2013;159(5):349–357. [PubMed: 23798026] 
52. Kentucky State Government. Kentucky legislature, senate bill 250. [cited 2018 April 30]. Available 
from: http://www.lrc.ky.gov/recorddocuments/bill/18RS/SB250/bill.pdf
53. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. 
HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2018 [cited 2018 
Jul 17]. Available from: https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/
HCVGuidance_May_24_2018a.pdf•• This has the latest recommendations for testing, managing 
and treating Hepatitis C Virus infection.
54. Coward S, Leggett L, Kaplan GG, et al. Cost-effectiveness of screening for hepatitis C virus: a 
systematic review of economic evaluations. BMJ Open. 2016;6(9):e011821.
55. Selvapatt N, Ward T, Bailey H, et al. Is antenatal screening for hepatitis C virus cost-effective? A 
decade’s experience at a London centre. J Hepatol. 2015;63(4):797–804. [PubMed: 26024832] 
56. Benova L, Awad SF, Abu-Raddad LJ. Estimate of vertical transmission of Hepatitis C virus in 
Pakistan in 2007 and 2012 birth cohorts. Journal of viral hepatitis. 2017; 12;24(12):1177–1183. 
[PubMed: 28662284] 
57. Benova L, Awad SF, Miller FD, et al. Estimation of hepatitis C virus infections resulting from 
vertical transmission in Egypt. Hepatology (Baltimore, Md). 2015;61(3):834–842.
58. Indolfi G, Guido M, Azzari C, et al. Histopathology of hepatitis C in children, a systematic review: 
implications for treatment. Expert Rev Anti Infect Ther. 2015;13(10):1225–1235. [PubMed: 
26202832] 
59. Di Marco V Chronic hepatitis C in children is a mild and curable liver disease. Digestive Liver Dis. 
2011;43(4):266–267.
60. Jonas MM. Children with hepatitis C. Hepatology (Baltimore, Md). 2002;36(5 I):S173–S8.
61. Indolfi G, Bartolini E, Serranti D, et al. C in children co-infected with human immunodeficiency 
virus. J Pediatr Gastroenterol Nutr. 2015;61(4):393–399. [PubMed: 26147631] 
62. Rao VB, Johari N, du Cros P, et al. Hepatitis C seroprevalence and HIV co-infection in sub-
Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(7):819–824. 
[PubMed: 25957078] 
63. Sokal E, Nannini P. Hepatitis C virus in children: the global picture. Hepatitis C virus in children: 
the global picture. Archives of disease in childhood. 2017;102(7):672–675. [PubMed: 28179270] 
64. Nydegger A, Srivastava A, Wake M, et al. Health-related quality of life in children with hepatitis C 
acquired in the first year of life. J Gastroenterol Hepatol. 2008;23(2):226–230. [PubMed: 
18289357] 
Nwaohiri et al. Page 10
Expert Rev Anti Infect Ther. Author manuscript; available in PMC 2019 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
65. Rodrigue JR, Balistreri W, Haber B, et al. Impact of hepatitis C virus infection on children and 
their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr. 
2009;48 (3):341–347. [PubMed: 19242286] 
66. Younossi ZM, Stepanova M, Balistreri W, et al. Health-related quality of life in adolescent patients 
with Hepatitis C genotype 1 treated with sofosbuvir and ledipasvir. J Pediatr Gastroenterol Nutr. 
2018;66(1):112–116. [PubMed: 28957984] • This study has shown that treatment of HCV infected 
adolescents increases their quality of life.
67. Jhaveri R, Grant W, Kauf TL, et al. The burden of hepatitis C virus infection in children: estimated 
direct medical costs over a 10-year period. J Pediatrics. 2006;148(3):353–358.
68. PEGASYS Prescribing Information. [cited 2017 June 9]. Available from: https://www.gene.com/
download/pdf/pegasys_prescribing.pdf
69. FDA approves two hepatitis C drugs for pediatric patients. 2017 [cited 2017 Jul 6]. Available from: 
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm551407.htm
70. Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir 
in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. Hepatology (Baltimore, 
Md). 2017;66(2):371–378.•• This clinical trial paved the way for the first approved DAA regimens 
for use in adolescents.
71. Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With 
HCV Infection. [cited 2017 June 12]. Available from: http://www.gilead.com/news/press-releases/
2017/4/gilead-announces-scientific-presentations-demonstrating-efficacy-of-harvoni-
ledipasvirsofosbuvir-in-special-patient-populations-with-hcv-infection
72. Murray KF, Balistreri W, Bansal S. Ledipasvir/sofosbuvir ± ribavirin for 12 or 24 weeks is safe and 
effective in children 6–11 years old with chronic hepatitis C infection. Amsterdam: Abstract 
GS-010. EASL International Liver Congress; 2017.
73. El-Shabrawi MHF, Kamal NM, El-Khayat HR, et al. A pilot single arm observational study of 
sofosbuvir/ledipasvir (200 + 45 mg) in 6- to 12- year old children. Alimentary pharmacology & 
therapeutics. 2018;47(12):1699–1704. [PubMed: 29696674] 
74. El-Khayat HR, Kamal EM, El-Sayed MH, et al. The effectiveness and safety of ledipasvir plus 
sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world 
experience. Aliment Pharmacol Ther. 2018;47(6):838–844. [PubMed: 29349793] 
75. Yakoot M, El-Shabrawi MH, AbdElgawad MM, et al. Dual sofosbuvir/daclatasvir therapy in 
adolescent patients with Chronic Hepatitis C Infection. J Pediatr Gastroenterol Nutr. 2018;67(1):
86–89. [PubMed: 29570560] 
76. US National Institutes of Health. [cited 2017 June 9]. Available from: http://www.clinicaltrials.gov
77. Annunziato RA, Lee SG, Galici E, et al. Children with Hepatitis C: the impact of disease and 
treatment on patients, caregivers and families. J Pediatr Nurs. 2017;32:8–11. [PubMed: 27836372] 
78. Hellard M, Pedrana A, Scott N. Targeted direct-acting antiviral treatment for chronic hepatitis C: A 
financial reality or an obstacle to elimination? J Hepatol. 2017;66(2):270–272. [PubMed: 
27884764] 
79. Rosenthal ES, Graham CS. Price and affordability of direct-acting antiviral regimens for hepatitis 
C virus in the United States. Infect Agent Cancer. 2016;11:24. [PubMed: 27186235] 
80. Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent Hepatitis B transmission in mothers with high 
viral load. N Engl J Med. 2016;374(24):2324–2334. [PubMed: 27305192] 
81. Nguyen P, Vutien P, Hoang J, et al. Barriers to care for chronic hepatitis C in the direct-acting 
antiviral era: a single-centre experience. BMJ Open Gastroenterol. 2017;4(1):e000181.
Nwaohiri et al. Page 11
Expert Rev Anti Infect Ther. Author manuscript; available in PMC 2019 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Key issues
• HCV is a treatable disease, yet it accounts for more than a quarter of liver 
cirrhosis and hepatocellular carcinoma worldwide.
• There is evidence that HCV is increasing in the U.S. This increase has been 
associated with the ongoing opioid epidemic.
• Children that do not undergo spontaneous clearance of the virus will go on to 
develop chronic HCV infection.
• There are no treatment options currently for HCV-infected pregnant women 
and 6%–11% of them will pass on the virus to their infants.
• Screening of pregnant women is largely risk-based in the United States and 
women are required to self-identify as high-risk for HCV screening. 
Therefore, the opportunity to identify at-risk children may be missed if 
women do not self-report their risk correctly.
• Second and third generation DAAs have shown excellent results in treating 
HCV infection in adult and adolescent populations and have been approved 
for use in children 12 years of age and older.
• For younger children (<12 years old), there are no FDA approved DAAs yet. 
Preliminary results from clinical trials demonstrate the efficacy of DAAs in 
children 6–12 years old.
• DAAs may be the key to elimination of HCV. Although significant barriers 
such as cost and accessibility remain.
• More research and clinical trials are needed to provide the evidence that will 
help shape the horizon on pediatric infections and infections during 
pregnancy.
Nwaohiri et al. Page 12
Expert Rev Anti Infect Ther. Author manuscript; available in PMC 2019 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
